PMID- 16516290
OWN - NLM
STAT- MEDLINE
DCOM- 20061108
LR  - 20151119
IS  - 0145-2126 (Print)
IS  - 0145-2126 (Linking)
VI  - 30
IP  - 10
DP  - 2006 Oct
TI  - MCP-1 in the cerebrospinal fluid of children with acute lymphoblastic leukemia.
PG  - 1259-61
AB  - BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) is a member of the CC 
      chemokines. MCP-1 has been previously shown to have a major role in the migration 
      of monocytes towards human leukemic cells, yet it cannot increase cytotoxic 
      effects of monocytes on human leukemic cells. AIM: To determine levels of MCP-1 
      in the CSF of children during various stages of acute lymphoblastic leukemia 
      (ALL). PATIENTS AND METHODS: A 19 children with ALL and without known CNS 
      involvement were enrolled in the study. CSF samples were aliquoted at different 
      stages of therapy (diagnosis, induction, and maintenance) and were frozen at -70 
      degrees C until use. MCP-1 was measured with a sandwich enzyme-linked 
      immunoabsorbent assay. RESULTS: Mean MCP-1 levels in the CSF were 1762.38 pg/ml 
      (range 522-5000 pg/ml). In children without CNS involvement at diagnosis, CSF 
      MCP1 levels did not change over time and remained within this range throughout 
      the diagnosis and treatment stages. CNS involvement was associated with an 
      increased MCP-1 level following chemotherapy, in patients with CNS involvement 
      from 840 to 3990 pg/ml (P<0.0001), and in patients without CNS involvement from 
      1134 to 1943 pg/ml (P-value of 0.0322). White blood cells found in the CSF at 
      diagnosis have vanished after induction. CONCLUSIONS: CNS involvement in ALL is 
      associated with significantly higher levels of MCP1 during therapy. This 
      significant rise in MCP-1 levels might be one of the mechanisms involved in the 
      regulation of CNS leukemia. Since chemokines target specific leukocyte subsets, 
      inhibition of a single Chemokine ligand or receptor may have a circumscribed 
      effect, endowing the inhibitor with a limited side effect profile. Chemokines 
      should be considered as possible targets for therapeutic intervention.
FAU - Eisenkraft, Arik
AU  - Eisenkraft A
AD  - Department of Pediatrics, Safra Children's Hospital, Sheba Medical Center, 
      Tel-Hashomer, Israel. aizenkra@017.net.il
FAU - Keidan, Ilan
AU  - Keidan I
FAU - Bielorai, Bela
AU  - Bielorai B
FAU - Keller, Nathan
AU  - Keller N
FAU - Toren, Amos
AU  - Toren A
FAU - Paret, Gideon
AU  - Paret G
LA  - eng
PT  - Journal Article
DEP - 20060303
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Adolescent
MH  - Biomarkers, Tumor/cerebrospinal fluid
MH  - Central Nervous System Diseases/cerebrospinal fluid/epidemiology
MH  - Chemokine CCL2/*cerebrospinal fluid
MH  - Child
MH  - Child, Preschool
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Male
MH  - Neoplasm Staging
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*cerebrospinal fluid/*drug 
      therapy/pathology
EDAT- 2006/03/07 09:00
MHDA- 2006/11/10 09:00
CRDT- 2006/03/07 09:00
PHST- 2005/12/14 00:00 [received]
PHST- 2005/12/14 00:00 [revised]
PHST- 2006/01/30 00:00 [accepted]
PHST- 2006/03/07 09:00 [pubmed]
PHST- 2006/11/10 09:00 [medline]
PHST- 2006/03/07 09:00 [entrez]
AID - S0145-2126(06)00053-1 [pii]
AID - 10.1016/j.leukres.2006.01.017 [doi]
PST - ppublish
SO  - Leuk Res. 2006 Oct;30(10):1259-61. doi: 10.1016/j.leukres.2006.01.017. Epub 2006 
      Mar 3.